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Exploring the role of ceftaroline in the 
treatment of community-acquired 
pneumonia 
ZACHARY MEYER, Wayne State University School of Medicine, fy3419@wayne.edu  
 
ABSTRACT A critical appraisal and clinical application of File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens 
L, Critchley IA, Thye DA, FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy 
and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66 Suppl 
3:iii19-32. doi: 10.1093/jac/dkr096. 
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Clinical Context 
The patient is a 68 year old African American woman with a past medical history of heart failure with preserved 
ejection fraction and chronic kidney disease stage II. She was hospitalized with community-acquired pneumonia 
(CAP) of Pneumonia Severity Index (PSI) risk class III after her symptoms began 2 days prior to admission. Her chest 
radiograph showed new pulmonary infiltrates and physical exam showed an increased cough, wheezing, positive 
whispered pectoriloquy, and dyspnea. The treatment team explored the current best treatment for CAP and the 
role of ceftaroline was considered. The patient was treated with intravenous ceftriaxone and azithromycin and was 
well enough for discharge after 3 nights. 
Clinical Question 
Would ceftaroline with a macrolide provide better clinical cure rates than ceftriaxone with a macrolide? 
Research Article 
File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 investigators. FOCUS 1: a 
randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in 
community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096 
Related Literature 
A search on UpToDate for ceftaroline in the treatment of community-acquired pneumonia yielded a page with references that 
included the one chosen for this critical appraisal. PubMed was then searched using the key words “ceftaroline ceftriaxone,” 
“ceftaroline ceftriaxone pneumonia,” and “ceftaroline pneumonia.” This yielded several hundred abstracts, which were then 
reviewed to determine that the best article had been chosen for appraisal. The FOCUS 1 and 2 trials were phase III, double-blinded, 
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randomized, multi-national, multicentre trials with nearly identical methods and results.1,2 These trials were chosen because of their 
quality and size, but the FOCUS 1 article was ultimately selected for two reasons: its larger number of patients in the same age range 
as this article’s patient, and the lack of Black or African American patients in the FOCUS 2 article. The patients were a mean age of 
61.1, approximately 90% white, 5% Asian, and 5% black, with pneumonia of PSI risk class III or IV, and very similar illness histories to 
this article’s patient. 298 patients received ceftaroline fosamil as the experiment group and 308 received ceftriaxone as the 
comparator group. Ultimately, 600 mg of ceftaroline iv every 12 h was demonstrated to be non-inferior to 1 g of ceftriaxone iv every 
24 h, achieving higher cure rates in hospitalized patients with CAP of PSI risk class III or IV across all predefined populations.1 
The only other high quality clinical trial was an international, randomized, controlled, double-blind, phase 3, non-inferiority with 
nested superiority trial, with only adult Asian patients suffering from PSI risk class III or IV community-acquired pneumonia. Subjects 
included 217 (84%) of 258 patients receiving ceftaroline fosamil and 178 (74%) of 240 patients receiving ceftriaxone were clinically 
cured. Ceftaroline fosamil was found to be superior to ceftriaxone in all patient groups except those under the age of 65. This study 
was not chosen because the patient population was the most different from my patient, it had fewer patients in the study, and there 
was high industry involvement resulting in an increased risk of selective outcome reporting.3 
There were a number of articles that delved into the efficacy of ceftaroline in patients with pneumonia, and most showed it to be 
either non-inferior or superior to ceftriaxone. However, these studies were inferior to the article chosen for critical review for 
reasons that included non-human patients, smaller study size, no comparison to ceftriaxone, pneumonia complications like 
bacteremia, and pediatric patients. None of these studies refuted the findings of the FOCUS 1 study and most were congruent with 
its conclusion of non-inferiority with ceftriaxone.4-13 
Critical Appraisal 
The study chosen for this appraisal was a phase III, double-blinded, randomized, multinational, multicentre trial, which is an 
excellent design to minimize bias on the part of the patients or the providers. The patients were randomized in a 1:1 ratio to each 
treatment group stratified by PSI risk class so that there was an even number of each risk class in both groups. The patients were 
also placed into the clinically evaluable (CE) population and/or the modified intent-to-treat efficacy (MITTE) population. The MITTE 
population included patients with community-acquired pneumonia of PSI risk class III or IV at the time of randomization. The authors 
report data on a “clinically evaluable” subgroup, but this group was so highly selective that these results are not useful for making 
clinical decisions. Only patients who had been diagnosed with CAP of PSI risk class III or IV that began within the last 7 days could 
enter this study; these criteria ensured patients were of a similar disease burden compared to this article’s patient. The intervention 
group received identical treatment compared with the control group except that the intervention group received ceftaroline as part 
of their treatment instead of ceftriaxone. A shortcoming of this study was the lack of details concerning outcome assessments. 
Everything was measured in microbiological outcomes and clinical cure rates; the criteria for these were somewhat unclear, but it 
was concluded to not impede the application of this research to other patient populations. It is also worth noting that 
pharmaceutical company Forest Laboratories provided the funding for this research, and Cerexa, Inc, a subsidiary of Forest 
Laboratories, performed the statistical analysis.1 
This study had the most similar patient population to our patient in regards to age and race. The only factor that would make using 
ceftaroline less feasible is the extremely high price of treatment that currently exists. Patients receiving ceftaroline or ceftriaxone, 
respectively, had drop out rates of 3.7% and 3.9% because of treatment-related adverse events. Diarrhea was the most common 
adverse event experienced in both treatment groups. It appears that blinding was successful in preventing both patients and 
providers from being biased, and both groups were able to be treated in nearly identical manners.1 
This double blinded, randomized, study comparing two treatments regarding their success rate and adverse effects has a level of 
evidence that could be labeled as 1b. Clinical cure rates were as follows: MITTE population, 83.4% (244/291) for ceftaroline and 
77.7% (233/300) for ceftriaxone. This means the number needed to treat was 16. The adverse events that resulted in 
discontinuation of treatment were as follows: 3.7% for ceftaroline and 3.9%. 
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Clinical Application 
The patient is a 68 year old African American woman with community acquired pneumonia of PSI risk class III. This 
study’s conclusion shows that ceftaroline is a non-inferior treatment for community acquired pneumonia when 
compared to ceftriaxone.1 The patient met the study’s inclusion criteria, however, despite the demonstrated 
noninferiority and the potential higher cure rates, using ceftaroline might not be the best initial choice for a 
community acquired pneumonia patients.1 It is typically the goal to use the least powerful antibiotic possible to 
cure a disease, therefore it is of questionable prudency to use a powerful antibiotic like ceftaroline as an initial 
treatment for community acquired pneumonia. 
Secondly, ceftaroline is a relatively new antibiotic, which means its use also comes with a heavy financial burden. 
With these two thoughts in mind, it seems that ceftriaxone is still the best choice in treating community-acquired 
pneumonia. The earlier clinical question arose from a desire to confirm this patient was receiving the best 
evidence based treatment, which requires an assessment of both risk of benefit and risk of harm. The patient could 
have arguably benefited from the potentially higher cure rates of ceftaroline. However, when cost and 
antimicrobial stewardship were considered, it was concluded that ceftriaxone was still the best treatment option. 
The patient completely recovered in a timely manner without complication. 
Learning points: 
1. Cases of community-acquired pneumonia with MRSA and drug resistant Streptococcus pneumoniae are on the 
rise. With the rising rates of drug resistant pneumonia and the impact such diseases have, it may become 
increasingly important to consider more effective antibiotics like ceftaroline.1 
2. Risk of harm and risk of benefit for newer antimicrobial agents need to be balanced with consideration for 
antimicrobial stewardship, cost, and adverse events. As diseases and guidelines evolve over time, it will be the 
duty of physicians to balance these concerns. 
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